Evolus (NASDAQ:EOLS) Stock Price Down 4.7% – Should You Sell?

Evolus, Inc. (NASDAQ:EOLS) was down 4.7% during mid-day trading on Monday . The stock traded as low as $9.59 and last traded at $9.57. Approximately 738,868 shares were traded during trading, a decline of 20% from the average daily volume of 929,089 shares. The stock had previously closed at $10.04.

Analyst Ratings Changes

Several analysts recently commented on EOLS shares. BTIG Research assumed coverage on Evolus in a research report on Thursday, April 17th. They issued a “buy” rating and a $21.00 target price on the stock. Needham & Company LLC reissued a “buy” rating and set a $22.00 price target on shares of Evolus in a report on Thursday, May 8th. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Finally, Barclays raised their target price on shares of Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $23.75.

Evolus Trading Down 4.0%

The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The business has a fifty day moving average of $10.39 and a 200-day moving average of $11.88. The stock has a market capitalization of $621.55 million, a price-to-earnings ratio of -10.57 and a beta of 1.00.

Insiders Place Their Bets

In related news, CFO Sandra Beaver sold 6,494 shares of Evolus stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $10.02, for a total value of $65,069.88. Following the transaction, the chief financial officer now directly owns 167,089 shares in the company, valued at $1,674,231.78. The trade was a 3.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Karah Herdman Parschauer sold 12,888 shares of the company’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now directly owns 32,183 shares of the company’s stock, valued at approximately $418,057.17. This represents a 28.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 86,241 shares of company stock worth $1,048,666. 5.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in EOLS. Nuveen LLC purchased a new stake in shares of Evolus in the 1st quarter valued at approximately $12,330,000. Tri Locum Partners LP purchased a new stake in shares of Evolus in the fourth quarter valued at $8,198,000. Gilder Gagnon Howe & Co. LLC boosted its position in shares of Evolus by 287.2% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock worth $7,753,000 after buying an additional 520,859 shares during the period. Caligan Partners LP grew its holdings in shares of Evolus by 22.7% during the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after buying an additional 498,900 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new position in Evolus during the first quarter valued at $5,851,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.